Crystallization of (20R,22R)-2-Methylene-19-Nor-22-Methyl-1alpha,25-Dihydroxyvitamin D3 and Related Precursors
    4.
    发明申请
    Crystallization of (20R,22R)-2-Methylene-19-Nor-22-Methyl-1alpha,25-Dihydroxyvitamin D3 and Related Precursors 有权
    (20R,22R)-2-亚甲基-19-诺-22-甲基-1α,25-二羟基维生素D 3和相关前体的结晶

    公开(公告)号:US20130324752A1

    公开(公告)日:2013-12-05

    申请号:US13828302

    申请日:2013-03-14

    IPC分类号: C07C401/00 C07C35/32

    摘要: Disclosed are methods of purifying the compound (20R,22R)-2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving a product containing the compound in a solvent comprising hexane and 2-propanol, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of crystals, and recovering the crystals. Certain diol precursors formed during the synthesis of the compound and its diasteromers also may be obtained in crystalline form using ethyl acetate as a solvent.

    摘要翻译: 公开了纯化化合物(20R,22R)-2-亚甲基-19-去甲-22-甲基-1α,25-二羟基维生素D3以获得结晶形式的化合物的方法。 所述方法通常包括以下步骤:将含有该化合物的产物溶解在包含己烷和2-丙醇的溶剂中,将溶剂和溶解的产品在环境温度下冷却足够的时间以形成晶体沉淀并回收晶体。 在合成化合物及其非对映体期间形成的某些二醇前体也可以使用乙酸乙酯作为溶剂以结晶形式获得。